Testing empagliflozin for heart problems in kids with Duchenne MD
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests if a type 2 diabetes medicine called empagliflozin can help children who have heart problems caused by Duchenne muscular dystrophy. If you are between 6 and 18 years old and already taking heart failure medications, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 to 18 years old with Duchenne muscular dystrophy and heart problems.
- You are already taking medicine for heart failure.
- Your doctor thinks adding empagliflozin might help you.
- Your heart medicines have been stable for at least 2 weeks before the study starts.
- You are able to have an MRI of your heart without needing anesthesia.
- You (or your parent/guardian) can understand and sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This clinical trial looks at whether adding a special diet supplement (ketones) to an SGLT2 inhibitor diabetes drug improves heart function and symptoms in people who have both type 2 diabetes and heart failure with a weakened heart muscle.
Hear when a new DMD-associated Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.